Tg Therapeutics (TGTX) Other Non-Current Liabilities (2010 - 2026)

Tg Therapeutics' Other Non-Current Liabilities history runs 13 years deep, the most recent figure standing at $777000.0 for Q1 2026.

• In Q1 2026, Other Non-Current Liabilities fell 64.08% year-over-year to $777000.0; the TTM figure through Mar 2026 stood at $777000.0 (down 64.08% YoY), while the FY2025 annual figure was $2.1 million, down 44.56% from the prior year.
• Other Non-Current Liabilities for Q1 2026 stood at $777000.0, down from $2.1 million in the prior quarter.
• The five-year high for Other Non-Current Liabilities was $3.8 million in Q4 2024, with the low at $243000.0 in Q4 2022.
• The 5-year median for Other Non-Current Liabilities is $2.2 million (2025), against an average of $2.1 million.
• The sharpest annual moves came in 2024 and 2026: Other Non-Current Liabilities surged 961.62% in 2024, then sank 64.08% in 2026.
• Tg Therapeutics' Other Non-Current Liabilities stood at $243000.0 in 2022, then soared by 46.91% to $357000.0 in 2023, then soared by 961.62% to $3.8 million in 2024, then sank by 44.56% to $2.1 million in 2025, then plunged by 63.02% to $777000.0 in 2026.
• Business Quant data shows TGTX's Other Non-Current Liabilities at $777000.0 in Q1 2026, $2.1 million in Q4 2025, and $2.0 million in Q3 2025.